Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions
Floc'h, Nicolas, Martin, Matthew J., Riess, Jonathan W., Orme, Jonathan P, Staniszewska, Anna D., Menard, Ludovic, Cuomo, Maria Emanuela, O'Neill, Daniel J., Ward, Richard A, Finlay, M. Raymond V., McLangue:
english
Journal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.MCT-17-0758
Date:
February, 2018
Fichier:
PDF, 1.14 MB
english, 2018